Boryung Co., Ltd. announced on June 18 that it has been selected as the final implementing agency for the 'Essential Drug Supply Stabilization Support Project' conducted by the Ministry of Health and Welfare and the Korea Health Industry Development Institute.
The 'Essential Drug Supply Stabilization Support Project' was launched this year for the first time to address drug supply instability and protect public health rights. The project aims to establish a stable drug supply chain by supporting production facilities and equipment for drugs with unstable domestic supply, thereby resuming and increasing supply.
Boryung's 'Boryung Quest Ran Suspension (active ingredient: cholestyramine resin)', which was selected as the first beneficiary of this support project through a public competition, is a bile acid sequestrant hyperlipidemia treatment. It is the only hyperlipidemia treatment in Korea that can be safely used by mothers and children in the era of low birth rates.
Through this project, Boryung plans to resume domestic production and launch of Quest Ran, whose supply was suspended in 2023 due to profitability issues, within this year. The company intends to quickly establish production facilities and obtain product approvals to build a stable supply system for this drug.
Jung Eunyoung, Director of the Health Industry Policy Division at the Ministry of Health and Welfare, stated, "This project, launched for the first time this year, is aimed at establishing a stable production base for essential medicines. The government will continue to expand necessary support in cooperation with domestic pharmaceutical companies to ensure the stable supply of medicines needed by the public."
A Boryung representative commented, "We are pleased to be able to continuously supply essential medicines for mothers and children through this meaningful support project," and added, "We will continue to play a leading role in ensuring the stable supply and localization of essential medicines necessary for public health and do our utmost to fulfill our public interest values."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
